Back to search

University of South Florida

Lymphatic Malformations with Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases

Abstract

dc:description

Lymphatic malformations (LMs) are lesions that can be due to inherited or somatic mutations, and they lead to a defective lymphatic vasculature. Activating KRAS mutations have been identified recently in LM patients with lymphedema, chylous ascites, or life-threatening chylothorax. In a LM mouse model, KRAS mutations are associated with a loss of lymphatic valves, which has been proposed to cause chylothorax via retrograde lymph flow into the pleural space. However, the mechanisms underlying the loss of lymphatic valves are unknown. To investigate the mechanisms leading to valve loss, we combined the lymphatic-specific and tamoxifen-inducible Flt4CreERT2 with Kras-loxP-stop-loxP-G12D (Kras+/G12D) mice and Prox1GFP reporter mice to induce the restricted expression of KRAS-G12D and enable valve quantification in postnatal pups. Human dermal lymphatic endothelial cells (hdLECs) expressing KRAS-G12D were probed for changes in mRNA and protein expression with qRT-PCR, western blot, and gel zymography, and mechanistic studies were performed using 3D cell culture in collagen matrices. Our data showed that lymphatic-specific expression of KRAS-G12D significantly attenuated valve development in the mesentery, diaphragm, and ear skin. qRT-PCR, western blot, and gel zymography using hdLECs expressing KRAS-G12D revealed the upregulation of the plasminogen activator (PA) pathway and matrix metalloproteinases (MMPs). The MMPs were sufficiently activated by plasmin, the product of the PA pathway, in hdLECs grown in a 3D collagen matrix, indicating a role for MMPs in the degradation of the valve extracellular matrix (ECM) core. Furthermore, a broad-spectrum MMP inhibitor given to Flt4CreERT2;Kras+/G12D mice rescued lymphatic valve development. We conclude that hyperactive KRAS signaling upregulates MMPs that become excessively activated by the upregulation of the PA pathway. MMPs then degrade the lymphatic valve ECM core preventing valve formation.

Degree

thesis:*
Name thesis:degree_name
Doctor of Philosophy (Ph.D.)
Level thesis:degree_level
Dissertation
Discipline thesis:degree_discipline
Medical Sciences
Grantor
University of South Florida
Year dc:date
2026

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Mastrogiacomo, Diandra M.
Contributors dc:contributor
  • Joshua P. Scallan, Ph.D.
  • Jerome W. Breslin, Ph.D.
  • Saulius Sumanas, Ph.D.
  • Yao Yao, Ph.D.

Subjects

dc:subject × 6

Identifiers

dc:identifier.*
Repository record dc:identifier
https://digitalcommons.usf.edu/etd/11345

Chain of custody

source
Harvested from
University of South Florida
Base URL
digitalcommons.usf.edu/do/oai/
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Mastrogiacomo, Diandra M.. Lymphatic Malformations with Activating KRAS Mutations Impair Lymphatic Valve Development Through Matrix Metalloproteinases. Dissertation thesis, University of South Florida, 2026. https://digitalcommons.usf.edu/etd/11345